Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Source: CNBC Markets ·
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Read the full story at CNBC Markets
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.